Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Applied Genetic Technologies (NASDAQ:AGTC) Stock Price

News headlines about Applied Genetic Technologies (NASDAQ:AGTC) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Applied Genetic Technologies earned a daily sentiment score of 0.01 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 44.3094532110537 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

AGTC has been the subject of a number of recent analyst reports. Cantor Fitzgerald set a $9.00 target price on shares of Applied Genetic Technologies and gave the company a “hold” rating in a research report on Friday, October 6th. Zacks Investment Research lowered shares of Applied Genetic Technologies from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 31st. HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of Applied Genetic Technologies in a research report on Wednesday, November 8th. Wedbush reiterated an “outperform” rating and issued a $9.00 target price on shares of Applied Genetic Technologies in a research report on Wednesday, November 8th. Finally, ValuEngine downgraded shares of Applied Genetic Technologies from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $10.17.

Shares of Applied Genetic Technologies (NASDAQ:AGTC) traded down $0.25 during midday trading on Wednesday, reaching $4.95. 145,687 shares of the company’s stock were exchanged, compared to its average volume of 127,713. Applied Genetic Technologies has a 52 week low of $3.25 and a 52 week high of $8.40. The firm has a market cap of $89.56, a P/E ratio of -19.04 and a beta of 1.61.

Applied Genetic Technologies (NASDAQ:AGTC) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.06. Applied Genetic Technologies had a negative net margin of 8.78% and a negative return on equity of 2.86%. equities analysts anticipate that Applied Genetic Technologies will post -1.14 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This news story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/31/applied-genetic-technologies-agtc-getting-somewhat-positive-press-coverage-study-shows.html.

Applied Genetic Technologies Company Profile

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).

Insider Buying and Selling by Quarter for Applied Genetic Technologies (NASDAQ:AGTC)

Receive News & Ratings for Applied Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply